HC Wainwright & Co. Reiterates Buy on Arcturus Therapeutics, Maintains $51 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a 'Buy' rating on Arcturus Therapeutics (NASDAQ:ARCT) and maintained a $51 price target.
September 05, 2023 | 4:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arcturus Therapeutics has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $51.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $51 indicates the firm's continued confidence in the stock's potential, which could lead to increased investor interest and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100